STOCK TITAN

Aim Immunotech - AIM STOCK NEWS

Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.

Overview of AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company engaged in the research and development of advanced therapeutics to address critical challenges in cancer therapy, immune-deficiency disorders, and viral diseases. With a robust focus on clinical research and strategic development, the company leverages cutting-edge biotechnology to transform the landscape of therapeutic solutions. Key industry terms such as immuno-pharma, therapeutics, and clinical trials are embedded in its research activities, underlining its commitment to modern, science-driven treatments.

Core Business Areas

AIM ImmunoTech concentrates on two major product categories. The first is an injectable formulation of naturally derived alpha interferon, designed to address specific sexually transmitted diseases, such as the treatment of certain genital warts. The second flagship therapeutic, Ampligen, is a macromolecular ribonucleic acid molecule deployed in clinical trials targeting conditions like chronic fatigue syndrome as well as multiple cancer types including renal cell carcinoma, malignant melanoma, and advanced recurrent ovarian cancer. The company’s interest in Ampligen also extends to exploring its potential as an adjuvant therapy in infectious diseases, as evidenced by its research in combination with interferon and other immune modulators.

Research, Development, and Collaborations

At the heart of AIM ImmunoTech's operations lies a rigorous commitment to clinical innovation. The company is actively involved in multi-phase clinical investigations for various conditions, including studies on refractory cancers and assessments of its drugs as vaccine adjuvants. Collaborations with esteemed institutions, such as research agreements with international partners including the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., further underscore its strategic approach to expanding the therapeutic applications of its products. These partnerships illustrate a balanced research model that addresses both immunotherapy and anti-viral research, exemplifying the company’s proficiency in navigating complex biomedical landscapes.

Operational Excellence and Strategic Positioning

AIM ImmunoTech has established itself within a competitive biopharmaceutical sector by consistently pursuing clinical research excellence and targeting unmet medical needs. Its therapeutic portfolio is designed to harness the body’s natural immune response while providing innovative clinical solutions across multiple health conditions. The company’s research efforts are supported by rigorous clinical trials and detailed investigations which focus on enhancing drug efficacy and safety. With its diversified pipeline, the company demonstrates a strategic approach to mitigating risks associated with clinical development and capitalizing on opportunities within the evolving landscape of cancer and viral treatment modalities.

Market Significance and Competitive Landscape

The company occupies a unique niche within the immuno-pharma market. Unlike larger, more diversified pharmaceutical companies, AIM ImmunoTech’s focused approach on specialized therapeutics positions it as a significant contributor to niche therapeutic areas that remain underexplored by mainstream industry players. Its collaborative research strategy and emphasis on innovative therapies such as Ampligen have helped bolster its standing within a highly competitive market. AIM’s approach combines the rigors of clinical research with strategic partnerships, ensuring that its products are developed with precision and scientific integrity.

Scientific Rigor and Clinical Expertise

Clinical investigations conducted by AIM ImmunoTech are characterized by meticulous study design and scientific scrutiny. The company has been involved in numerous phase 1, 2, and exploratory trials that seek to validate the efficacy of its compounds across various challenging conditions. By integrating detailed clinical protocols and a commitment to evidence-based research, AIM ImmunoTech showcases a depth of expertise and a nuanced understanding of the interrelationships between diverse medical conditions such as cancer, chronic fatigue syndrome, and viral infections.

Conclusion

Overall, AIM ImmunoTech Inc. stands as a model of focused innovation within the immuno-pharma sector. Its sustained commitment to advancing clinical research, developing groundbreaking therapeutics, and fostering strategic international collaborations provides a comprehensive insight into its business operations. For those seeking an in-depth understanding of a company dedicated to transforming therapeutic paradigms in oncology and virology, AIM ImmunoTech represents a case study in applied scientific expertise and clinical diligence.

Rhea-AI Summary
AIM ImmunoTech Inc. releases CEO Corner segment discussing Advanced Recurrent Ovarian Cancer and clinical development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) will present at the Virtual Investor Lunch Break event with CEO Tom Equels on March 20th, discussing the company's business outlook and opportunities. The live video webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
AIM ImmunoTech Inc. launches CEO Corner featuring Thomas K Equels to provide additional perspective on press releases, corporate developments, and pipeline progress. The platform aims to connect directly with stockholders, offering expanded insights on clinical trials and corporate advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none
Rhea-AI Summary
AIM ImmunoTech Inc. highlights progress in Ampligen clinical development programs for various indications, including Post-COVID conditions, pancreatic cancer, and ovarian cancer. Recent accomplishments include positive results in the AMP-518 study and the DURIPANC study. The company emphasizes building upon scientific success and anticipates significant value for stockholders. Upcoming milestones include interim results for advanced recurrent ovarian cancer and final dataset for Post-COVID conditions in Q1 and Q2 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced the dosing of the first subject in a Phase 1b/2 clinical trial combining Ampligen with Imfinzi for late-stage pancreatic cancer treatment. The study is expected to be completed within six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive topline results from Phase 2 study of Ampligen in treating Post-COVID fatigue. Initial analysis shows lower fatigue levels in Ampligen group at multiple time points. The Six-Minute Walk Test also reveals a higher impact of Ampligen on distance traveled compared to placebo. Safety results indicate Ampligen is generally well-tolerated with no severe adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
clinical trial covid-19
Rhea-AI Summary
AIM ImmunoTech Inc. has received authorization from the Erasmus Medical Center Ethics Committee to open a European site for the ongoing Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer. The approval is a significant step towards enrolling subjects in the European arm of the clinical trial. The study aims to compare the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Subject enrollment is expected in Q1 2024, with approximately 90 subjects to be enrolled in the United States and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced the enrollment of the first subject in a Phase 1b/2 clinical trial combining Ampligen with AstraZeneca’s Imfinzi for late-stage pancreatic cancer treatment. Positive clinical data could make AIM an attractive buyout target. AIM secured a U.S. patent for Ampligen's use in combination therapy. The trial aims to determine safety and clinical benefit rates of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the opening of enrollment in a Phase 1b/2 clinical trial at Erasmus Medical Center in Rotterdam, Netherlands, for the treatment of pancreatic cancer. The trial will combine AIM's Ampligen with AstraZeneca's Imfinzi, aiming to determine the safety and clinical benefit rate of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announces the election of all four directors at the 2023 Annual Meeting of Stockholders. The company expresses gratitude to shareholders and emphasizes commitment to delivering life-saving treatments and creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none

FAQ

What is the current stock price of Aim Immunotech (AIM)?

The current stock price of Aim Immunotech (AIM) is $0.125 as of April 1, 2025.

What is the market cap of Aim Immunotech (AIM)?

The market cap of Aim Immunotech (AIM) is approximately 8.7M.

What is the core focus of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. is primarily focused on the research and development of novel therapeutics to treat various forms of cancer, immune-deficiency disorders, and viral diseases.

What are the main therapeutic products developed by AIM ImmunoTech?

The company develops products such as an injectable formulation of natural alpha interferon for certain STDs and Ampligen, a macromolecular RNA-based molecule investigated for cancer, chronic fatigue syndrome, and viral infections.

How does AIM ImmunoTech position itself within the biopharmaceutical industry?

The company positions itself by focusing on specialized therapeutic areas and leveraging robust clinical research and collaborations with renowned international partners to validate its compounds.

What is the significance of Ampligen in AIM ImmunoTech’s product portfolio?

Ampligen plays a key role as a versatile therapeutic candidate that is being evaluated for its efficacy in treating a range of conditions including various cancers, chronic fatigue syndrome, and its potential as a vaccine adjuvant.

How does the company approach clinical research and product development?

AIM ImmunoTech emphasizes rigorous clinical trial methodologies, strategic partnerships, and detailed research protocols to ensure that its therapeutic candidates meet high standards of safety and efficacy.

What distinguishes AIM ImmunoTech from other companies in the immuno-pharma sector?

Its focused approach on niche therapeutic areas, commitment to innovative clinical research, and strategic international collaborations allow AIM ImmunoTech to address unmet medical needs and differentiate itself within a competitive market.
Aim Immunotech

NYSE:AIM

AIM Rankings

AIM Stock Data

8.74M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
OCALA